The gene expression changes seen after Aza treatment mimicked the signature found in Cdx2 expressing cells prior to AML transformation (Fig. 7m), suggesting that Aza may revert AML to a pre-leukemic state, and also upregulates Klf4 (Fig. 7l), a gene known to be repressed by Cdx2 and has been shown to have a tumor suppressor function in AML21. The gene discussed is CDX2; the disease is acute myeloid leukemia.